Impact Report 2020/2021
Lung Foundation Australia's 2020/2021 Annual Report featuring the organisation's key highlights.View more
For 31 years we have been the trusted lung health charity working towards a future free from lung disease and lung cancer, our nation’s second leading cause of death. Since 1990, thanks to our generous community, we have raised and invested over $40.9 million in life-changing research. We have been at the forefront providing meaningful support, driving policy change and increasing awareness to give hope to the 1 in 3 Australians impacted by lung disease or lung cancer.
Pictured: Parents Georgie and Shaun with their daughter Eve, who lives with a rare lung disease.
This year we were proud to launch the Hope Research Fund, our 10-year commitment to driving life-changing lung disease and lung cancer research. This Fund forms part of our mission to become one of the nation’s leading investors in lung health research, with the goal to raise $50 million by 2030 to support ground-breaking discoveries in prevention, diagnosis, treatment and cure. The Fund launched in April 2021 with over $9 million invested through major gifts and bequests. With money raised through the generosity of the community and together with our partners, our renowned research program continued to drive advancements by funding innovative research projects and fostering collaboration with leading Australian researchers. Together, we achieved the following.
After 10 years of successful operation, the Australian Idiopathic Pulmonary Fibrosis (IPF) Registry is being finalised. Recognised as an international leader, the Registry has had over 860 participants, the data has informed 19 publications in peer reviewed journals and 66 papers.
The Australasian Interstitial Lung Disease Registry will continue to drive greater research impact with a broader focus beyond IPF. More than 20 sites are participating across both Australia and New Zealand, with over 2,000 registry participants.
The Australian Bronchiectasis Registry is the only registry worldwide to hold longitudinal data on both adult and paediatric patients with bronchiectasis. It was established to facilitate epidemiological research in bronchiectasis and drive improvements in quality of care for patients.
The Pulmonary Fibrosis Australasian Clinical Trials Network endorsed and listed 7 new clinical trials, with more trials underway than ever before. The Consumer Advisory Group was formed to provide invaluable consumer input for researchers at all stages of the research process.
Government funding was secured to deliver recommendations made in the National Strategic Action Plan for Lung Conditions. This includes:
Pictured: Georgia, living with lung cancer, and her family.
Underpinned by evidence-based guidelines and informed directly by the needs and lived experience of our consumer community, our clinical programs are designed to translate research into practice for Australia’s lung health workforce and support improvements to the quality of care provided to people living with lung disease and lung cancer. Our national network of clinicians and health professionals generously donated almost 1,000 hours of their time, through the COVID-19 pandemic, to support us in the design and implementation of evidence-based guidelines, clinical resources, community of practice forums and education. Together we have achieved:
Pictured: Michelle, living with bronchiectasis, her son Max and husband Phillip.